U.S. Renal Care
5851 Legacy Circle Suite 900, Plano, TX, 75024, United States
Overview
U.S. Renal Care is a healthcare service provider that focuses on serving patients in dialysis facilities. It provides services to more than 25,000 patients in 335 dialysis facilities in 32 states and the Territory of Guam. The company has a business model, developing, and operating dialysis centers in joint venture partnerships with local nephrologists. U.S. Renal Care was founded in 2000 by Christopher Brengard and Jack Harrington and it is based in Plano, Texas.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 7
Sector focus
- Biotechnology
- Health Care
- Medical
Investment portfolio
- R1 Therapeutics
Participated · Series A · Mar 2026
R1 Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for patients with kidney disease. Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis and is described as a pan phosphate active transport inhibitor that blocks three key phosphate transporters in the gut. R1 positions AP306 as designed to deliver rapid and effective phosphate lowering with a reduced treatment burden. The company is partnering with Alebund on AP306 and plans to start a Phase 2b study later this year. R1 is led by Co-Founder, President and CEO Krishna Polu and is based in Redwood City, CA. The company strengthened its balance sheet with a $77.5M Series A to support its global development program.